Skip to menu Skip to content Skip to footer

2024

Journal Article

Effects of thiopurine withdrawal on vedolizumab-treated patients with ulcerative colitis: a randomized controlled trial

Pudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj, Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark G., De Cruz, Peter, Fung, Caroline Lan-San, Redmond, Diane, Chan, Webber, Mourad, Fadi, Kermeen, Melissa and Leong, Rupert W. (2024). Effects of thiopurine withdrawal on vedolizumab-treated patients with ulcerative colitis: a randomized controlled trial. Clinical Gastroenterology and Hepatology, 22 (11), 2299-2308. doi: 10.1016/j.cgh.2024.04.019

Effects of thiopurine withdrawal on vedolizumab-treated patients with ulcerative colitis: a randomized controlled trial

2024

Journal Article

Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial

Choy, Matthew C., Li Wai Suen, Christopher F. D., Con, Danny, Boyd, Kristy, Pena, Raquel, Burrell, Kathryn, Rosella, Ourania, Proud, David, Brouwer, Richard, Gorelik, Alexandra, Liew, Danny, Connell, William R., Wright, Emily K., Taylor, Kirstin M., Pudipeddi, Aviv, Sawers, Michelle, Christensen, Britt, Ng, Watson, Begun, Jakob, Radford-Smith, Graham, Garg, Mayur, Martin, Neal, van Langenberg, Daniel R., Ding, Nik S., Beswick, Lauren, Leong, Rupert W., Sparrow, Miles P. and De Cruz, Peter (2024). Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. The Lancet Gastroenterology & Hepatology, 9 (11), 981-996. doi: 10.1016/s2468-1253(24)00200-0

Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial

2024

Journal Article

Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: a systematic review and future perspective

Parigi, Tommaso Lorenzo, Solitano, Virginia, Armuzzi, Alessandro, Acosta, Manuel Barreiro de, Begun, Jake, Ben-Horin, Shomron, Biedermann, Luc, Colombel, Jean-Frederic, Dignass, Axel, Fumery, Mathurin, Ghosh, Subrata, Kobayashi, Taku, Louis, Edouard, Magro, Fernando, Panaccione, Remo, Rausch, Astrid, Reinisch, Walter, Selinger, Christian, Jairath, Vipul, Danese, Silvio and Peyrin-Biroulet, Laurent (2024). Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: a systematic review and future perspective. United European Gastroenterology Journal, 12 (9), 1266-1279. doi: 10.1002/ueg2.12671

Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: a systematic review and future perspective

2024

Conference Publication

The Efficacy of Maintenance Treatment with Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase History

Allegretti, Jessica R., Panés, Julián, Peyrin-Biroulet, Laurent, Sands, Bruce E., Yarandi, Shadi, Huang, Kuan-Hsiang G., Germinaro, Matthew, Zhan, Jia, Zhang, Hongyan, Begun, Jakob, Kierkuś, Jarosław, Kravchenko, Tetiana, Hisamatsu, Tadakazu, Rubin, David T., Bressler, Brian and Dignass, Axel (2024). The Efficacy of Maintenance Treatment with Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase History. 2024 ACG Annual Meeting, Philadelphia, PA United States, 25-30 October 2024. Philadelphia, PA United States: Lippincott Williams & Wilkins. doi: 10.14309/01.ajg.0001034328.68326.43

The Efficacy of Maintenance Treatment with Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase History

2024

Journal Article

International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement

Lu, Cathy, Rosentreter, Ryan, Parker, Claire E., Remillard, Julie, Wilson, Stephanie R., Baker, Mark E., Bhatnagar, Gauraang, Begun, Jakob, Bruining, David H., Bryant, Robert V., Christensen, Britt, Feagan, Brian G., Fletcher, Joel G., Gordon, Ilyssa, Henderson, Gaylyn, Jairath, Vipul, Knudsen, John, Kucharzik, Torsten, Lesack, Kyle, Maaser, Christian, Maconi, Giovanni, Novak, Kerri, Rimola, Jordi, Taylor, Stuart A., Wilkens, Rune, Rieder, Florian and on behalf of the Stenosis Therapy and Anti-Fibrotic Research (STAR) consortium (2024). International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement. The Lancet Gastroenterology & Hepatology, 9 (12), 1101-1110. doi: 10.1016/s2468-1253(24)00265-6

International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement

2024

Journal Article

Group B Streptococcus vaginal colonisation throughout pregnancy is associated with decreased Lactobacillus crispatus and increased Lactobacillus iners abundance in the vaginal microbial community

Maidment, Toby I., Pelzer, Elise S., Borg, Danielle J., Cheung, Eddie, Begun, Jake, Nitert, Marloes Dekker, Rae, Kym M., Clifton, Vicki L. and Carey, Alison J. (2024). Group B Streptococcus vaginal colonisation throughout pregnancy is associated with decreased Lactobacillus crispatus and increased Lactobacillus iners abundance in the vaginal microbial community. Frontiers in Cellular and Infection Microbiology, 14 1435745, 1-11. doi: 10.3389/fcimb.2024.1435745

Group B Streptococcus vaginal colonisation throughout pregnancy is associated with decreased Lactobacillus crispatus and increased Lactobacillus iners abundance in the vaginal microbial community

2024

Conference Publication

Healthcare utilisation in people with inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program

Su, Wai Kin, Pipicella, Joseph, Wilson, William, Kim, Andrew, Davidson, Chloe, Giles, Edward, Walker, Gareth, Forbes, Angela, Su, Heidi, Lawrance, Ian, Dutt, Shoma, Lynch, Kate, Brett, Laurel, Begun, Jakob, Connor, Susan J. and Andrews, Jane (2024). Healthcare utilisation in people with inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

Healthcare utilisation in people with inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program

2024

Conference Publication

The prevalence and impact of obesity in an ANZ cohort of people with inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program

Kaazan, Patricia, Su, Wai Kin, Rayner, Christopher, Walker, Gareth, Wilson, William, Dinoy, Elaine, Wark, Gabrielle, Forbes, Angela, Schultz, Michael, Yap, Jia, Lawrance, Ian, Dutt, Shoma, Lynch, Kate, Brett, Laurel, Begun, Jakob, Andrews, Jane and Connor, Susan J. (2024). The prevalence and impact of obesity in an ANZ cohort of people with inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

The prevalence and impact of obesity in an ANZ cohort of people with inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program

2024

Conference Publication

Mortality in inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program

Alsulaibi, Owen, Su, Wai Kin, Wilson, William, Sin, Hiu Ching Letisia, Ng, Watson, Walker, Gareth, Forbes, Angela, Lawrance, Ian, Lynch, Kate, Begun, Jakob, Connor, Susan J. and Andrews, Jane (2024). Mortality in inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

Mortality in inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program

2024

Conference Publication

Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis

Huynh, David, Khaing, Myat, Fernandes, Richard, Malloy, Reuben, Lin, Lei, Gilmore, Robert, Walker, Nicole, Khoo, Emi and Begun, Jakob (2024). Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2022, Sydney, NSW Australia, 9 - 11 September 2022. Richmond, VIC Australia: John Wiley & Sons. doi: 10.1111/jgh.16702

Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis

2024

Conference Publication

Topical upadacitinib is effective in distal ulcerative colitis: A case study and pre-clinical proof of concept

Giri, Rabina, Amiss, Anna, Riches, Bruce, Carpinelli De Jesus, Matheus and Begun, Jakob (2024). Topical upadacitinib is effective in distal ulcerative colitis: A case study and pre-clinical proof of concept. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

Topical upadacitinib is effective in distal ulcerative colitis: A case study and pre-clinical proof of concept

2024

Conference Publication

The psycho-social impact of fistulising perianal Crohn's disease in Australasia: Crohn's Colitis Cure (CCC) data insights program

Nano, Dominique, Su, Wai Kin, Mcnamara, Jack, Wilson, William, Arzivian, Arteen, Williams, Astrid-Jane, Walker, Gareth, Forbes, Angela, Su, Heidi, Giles, Edward, Lawrance, Ian, Dutt, Shoma, Lynch, Kate, Brett, Laurel, Begun, Jakob, Andrews, Jane and Connor, Susan J. (2024). The psycho-social impact of fistulising perianal Crohn's disease in Australasia: Crohn's Colitis Cure (CCC) data insights program. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

The psycho-social impact of fistulising perianal Crohn's disease in Australasia: Crohn's Colitis Cure (CCC) data insights program

2024

Conference Publication

A cross section of inflammatory bowel disease management in older persons in Australasia: Crohn's Colitis Cure (CCC) data insights program

Seng, Crystal, Su, Wai Kin, Wilson, William, Haifer, Craig, Williams, Astrid-Jane, Forbes, Angela, Lawrance, Ian, Lynch, Kate, Brett, Laurel, Begun, Jakob, Connor, Susan J., Andrews, Jane and Walker, Gareth (2024). A cross section of inflammatory bowel disease management in older persons in Australasia: Crohn's Colitis Cure (CCC) data insights program. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

A cross section of inflammatory bowel disease management in older persons in Australasia: Crohn's Colitis Cure (CCC) data insights program

2024

Conference Publication

Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case series

Swe, Ei Phyu Phyu, Gilmore, Robert, Murali, Amrutha, Etchegaray, Amirah, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2024). Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case series. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case series

2024

Conference Publication

Janus kinase inhibitors for the management of acute severe ulcerative colitis: An Australian multicentre study

Gilmore, Robert, Fernandes, Richard, Subhaharan, Deloshaan, Mohsen, Waled, Thin, Lena, Chin, Simone, Con, Danny, De Cruz, Peter, Demase, Kathryn, Sparrow, Miles P., Lucas, Sarah, Garg, Mayur, Bryant, Robert, Segal, Jonathan, Christensen, Britt, Begun, Jakob and An, Yoon-Kyo (2024). Janus kinase inhibitors for the management of acute severe ulcerative colitis: An Australian multicentre study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

Janus kinase inhibitors for the management of acute severe ulcerative colitis: An Australian multicentre study

2024

Conference Publication

Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis

Khoo, Emi, Amiss, Anna, Lindsay, Niamh, Fernandes, Richard, Gilmore, Robert, Ding, John Nik, Connor, Susan J., Bryant, Robert, White, Lauren, Mohsen, Waled, Leong, Rupert, Ardalan, Zaid, Croft, Anthony, De Cruz, Peter, Lynch, Kate, An, Yoon-Kyo, Holtmann, Gerald and Begun, Jakob (2024). Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis

2024

Conference Publication

Age-dependent dysregulation of the UPR in colonic epithelium: Implications for mucosal integrity

Illankoon, Thishan, Wong, Kuan Yau, Sajiir, Haressh, Mueller, Alexandra, Amiss, Anna, Begun, Jakob, Giri, Rabina, Burr, Lucy and Hasnain, Sumaira (2024). Age-dependent dysregulation of the UPR in colonic epithelium: Implications for mucosal integrity. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons.

Age-dependent dysregulation of the UPR in colonic epithelium: Implications for mucosal integrity

2024

Journal Article

Reliability of intestinal ultrasound for evaluating Crohn’s disease activity using point-of-care and central reading

Goodsall, Thomas M., An, Yoon-Kyo, Andrews, Jane M., Begun, Jakob, Friedman, Antony B., Lee, Andrew, Lewindon, Peter J., Spizzo, Paul, Rodgers, Nick, Taylor, Kirstin M., White, Lauren S., Wilkens, Rune, Wright, Emily K., Zou, Lily, Maguire, Bryan R., Parker, Claire E., Rémillard, Julie, Novak, Kerri L., Panaccione, Remo, Feagan, Brian G., Jairath, Vipul, Ma, Christopher and Bryant, Robert V. (2024). Reliability of intestinal ultrasound for evaluating Crohn’s disease activity using point-of-care and central reading. Clinical Gastroenterology and Hepatology. doi: 10.1016/j.cgh.2024.08.007

Reliability of intestinal ultrasound for evaluating Crohn’s disease activity using point-of-care and central reading

2024

Journal Article

A truncation mutant of adenomatous polyposis coli impairs apical cell extrusion through elevated epithelial tissue tension

Gan, Wan J., Giri, Rabina, Begun, Jakob, Abud, Helen E., Hardeman, Edna C., Gunning, Peter W., Yap, Alpha S. and Noordstra, Ivar (2024). A truncation mutant of adenomatous polyposis coli impairs apical cell extrusion through elevated epithelial tissue tension. Cytoskeleton, 82 (7), 444-455. doi: 10.1002/cm.21893

A truncation mutant of adenomatous polyposis coli impairs apical cell extrusion through elevated epithelial tissue tension

2024

Journal Article

Impact of a Patient Support Program on time to discontinuation of adalimumab in Australian adult patients with immunemediated inflammatory diseases-an observational study

Jones, Graeme, Calao, Miriam, Begun, Jakob, Sin, Shirley, Kouhkamari, Mahsa H., Young, Elisa, Fernández-Peñas, Pablo, Watts, Alan and Östör, Andrew J. (2024). Impact of a Patient Support Program on time to discontinuation of adalimumab in Australian adult patients with immunemediated inflammatory diseases-an observational study. PLoS One, 19 (6 June) e0300624. doi: 10.1371/journal.pone.0300624

Impact of a Patient Support Program on time to discontinuation of adalimumab in Australian adult patients with immunemediated inflammatory diseases-an observational study